Europe Molecular Diagnostics for Infectious Disease Market Forecast to 2030 - Regional Analysis - by Type (Point-of-Care Testing and Laboratory Testing), End User, Application, Disease Type, Infection Type

Description

List of Tables

The Europe molecular diagnostics for infectious disease market was valued at US$ 2,346.42 million in 2022 and is expected to reach US$ 5,948.40 million by 2030; it is estimated to grow at a CAGR of 12.3% from 2022 to 2030.

Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases Fuels the Europe Molecular Diagnostics for Infectious Disease Market

Diagnostic technologies that can detect emerging infectious animal diseases at an early stage are essential for reducing economic losses associated with outbreaks of such diseases. Polymerase chain reaction (PCR) remains the most widely used molecular assay globally for detecting animal pathogens. Diagnostic methods of this type are easy to use, cost-effective, highly sensitive, and specific, with the ability to detect at a high volume.

Point-of-care diagnostics (POCDs) are simple, rapid, and portable diagnostic devices that can detect the disease status at the field level. In recent years, real-time PCR (qPCR) has been transitioned into a POCD platform. These fully automated platforms combine nucleic acid extraction, thermal cycling, and on-site reporting results. For instance, MiniLab from Enigma Diagnostics is a molecular diagnostic platform of 10-35 kg that is carried at the field level and used for validating swine fever virus, avian influenza virus, classical swine fever virus, and foot-and-mouth disease virus for research purposes. The genesig detection kits of Primerdesign Ltd, UK, supplies lyophilized qPCR assay kits for the diagnosis of 62 bovine, 42 equine, 47 porcine, 60 avian, 40 canine, and 26 feline pathogens for research purposes. Similarly, Boster offers Bosterbio qPCR kits to detect up to 48 individual or pooled samples. It is used for gene expression profiling, target DNA quantification, microbial detection, viral or bacterial pathogen load determination, and evaluation of primer pair performance for probe-based qPCR.

Thus, molecular diagnostics methods such as PCR and qPCR to diagnose bacterial, viral, fungal, and parasitic infections in animals can replace the conventional methods such as serological, microscopic, and culture-based techniques.

Europe Molecular Diagnostics for Infectious Disease Market Overview

The European molecular diagnostics for infectious disease market is segmented into Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe. The region holds a significant share of the global molecular diagnostics for infectious disease market and is expected to register a notable CAGR during 2022-2030. The market growth in Europe is attributed to an upsurge in life science research and an increase in government investments in testing infectious diseases. According to the data published in an article by the Robert Koch Institute, ~3,900 tuberculosis cases were registered in Germany in 2021. According to this study, ~5% of the test-site visitors in Germany had STD. Moreover, the number of annual visitors for chlamydia and gonorrhea tests had increased from 17% (2017) to 42% (2020). As per the INSTITUT PASTEUR, in France, influenza affects 2-8 million people each year; 10,000-15,000 patients succumb to death due to influenza. It has become a public health issue due to its seasonal outbreaks every year. Other viral infections are also on the rise in the country. As per INSTITUT PASTEUR, 134,000 people are living with chronic hepatitis C virus (HCV) infection, with the addition of ~4,000 new cases annually. According to the WHO, in 2020, ~13,786 deaths were reported due to infectious and parasitic diseases in Italy. Similarly, ~1,303 HIV cases were diagnosed with an incidence of 2.2 per 100,000 residents. As per the Population Reference Bureau, the aging population in Italy was 24% in 2022, which is expected to reach 30% by 2040. Techniques that are used in molecular diagnostic applications are core molecular biology methods such as PCR amplification, sequencing, nucleic acid isolation and quantification, and STR analysis.

Europe Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

Europe Molecular Diagnostics for Infectious Disease Market Segmentation

The Europe molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger Europe molecular diagnostics market for infectious disease market share in 2022.

The Europe molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger Europe molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger Europe molecular diagnostics market for infectious disease market share in 2022.

Based on application, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the Europe molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The Point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest Europe molecular diagnostics for infectious disease market share in 2022.

Based on country, the Europe molecular diagnostics for infectious disease market is categorized into Germany, the UK, France, Italy, Spain, Austria, Belgium, the Netherlands, Luxembourg, and the Rest of Europe. Germany dominated the Europe molecular diagnostics for infectious disease market in 2022.

Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Molzym GmbH & Co KG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the Europe molecular diagnostics for infectious disease market.

Product Code: BMIRE00029840

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Europe Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Surging Prevalence of Infectious Disease Globally
- 4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
- 4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
- 4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
- 4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:

5. Molecular Diagnostic for Infectious Diseases Market - Europe Market Analysis

5.1 Europe Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030

6. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
- 6.3.1 Overview
- 6.3.2 Point-of-Care Testing: Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
- 6.4.1 Overview
- 6.4.2 Laboratory Testing: Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by End User

7.1 Overview
7.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
- 7.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 7.2.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)

8. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
- 8.3.1 Overview
- 8.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
8.4 Laboratory Testing
- 8.4.1 Overview
- 8.4.2 Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)

9. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Disease Type

9.1 Overview
9.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
- 9.3.1 Overview
- 9.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
  - 9.3.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
9.4 Laboratory Testing
- 9.4.1 Overview
- 9.4.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
  - 9.4.2.1 Europe Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)

10. Europe Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Infection Type

10.1 Overview
10.2 Europe Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
- 10.3.1 Overview
- 10.3.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
10.4 Laboratory Testing
- 10.4.1 Overview
- 10.4.2 Europe Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

11. Europe Molecular Diagnostic for Infectious Diseases Market - Country Analysis

11.1 Europe Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast to 2030
- 11.1.1 Overview
- 11.1.2 Europe Molecular Diagnostic for Infectious Diseases Market, by Country
  - 11.1.2.1 UK
    - 11.1.2.1.1 UK Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.1.2 UK: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.1.3 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.1.4 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.1.5 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.1.6 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.1.7 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.1.7.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.1.8 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.1.8.1 UK: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.1.9 UK: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.1.10 UK: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.2 Germany
    - 11.1.2.2.1 Germany Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.2.2 Germany: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.2.3 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.2.4 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.2.5 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.2.6 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.2.7 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.2.7.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.2.8 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.2.8.1 Germany: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.2.9 Germany: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.2.10 Germany: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.3 France
    - 11.1.2.3.1 France Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.3.2 France: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.3.3 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.3.4 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.3.5 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.3.6 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.3.7 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.3.7.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.3.8 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.3.8.1 France: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.3.9 France: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.3.10 France: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.4 Italy
    - 11.1.2.4.1 Italy Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.4.2 Italy: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.4.3 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.4.4 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.4.5 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.4.6 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.4.7 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.4.7.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.4.8 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.4.8.1 Italy: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.4.9 Italy: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.4.10 Italy: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.5 Spain
    - 11.1.2.5.1 Spain Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.5.2 Spain: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.5.3 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.5.4 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.5.5 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.5.6 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.5.7 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.5.7.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.5.8 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.5.8.1 Spain: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.5.9 Spain: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.5.10 Spain: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.6 Austria
    - 11.1.2.6.1 Austria Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.6.2 Austria: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.6.3 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.6.4 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.6.5 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.6.6 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.6.7 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.6.7.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.6.8 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.6.8.1 Austria: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.6.9 Austria: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.6.10 Austria: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.7 Belgium
    - 11.1.2.7.1 Belgium Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.7.2 Belgium: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.7.3 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.7.4 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.7.5 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.7.6 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.7.7 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.7.7.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.7.8 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.7.8.1 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.7.9 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.7.10 Belgium: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.8 Luxembourg
    - 11.1.2.8.1 Luxembourg Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.8.2 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.8.3 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.8.4 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.8.5 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.8.6 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.8.7 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.8.7.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.8.8 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.8.8.1 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.8.9 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.8.10 Luxembourg: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.9 The Netherlands
    - 11.1.2.9.1 The Netherlands Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.9.2 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.9.3 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.9.4 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.9.5 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.9.6 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.9.7 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.9.7.1 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.9.8 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.9.8.1 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.9.9 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.9.10 The Netherlands: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.10 Rest of Europe
    - 11.1.2.10.1 Rest of Europe Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.10.2 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.10.3 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.10.4 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.10.5 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.10.6 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.10.7 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.10.7.1 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.10.8 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.10.8.1 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.10.9 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.10.10 Rest of Europe: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
- 12.3.1 Overview
12.4 Inorganic Developments
- 12.4.1 Overview

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Abbott Laboratories
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 bioMerieux SA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Danaher Corp
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Hologic Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens Healthineers AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bruker Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Molzym GmbH & Co KG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 DiaSorin SpA
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms